NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 383 filers reported holding NEKTAR THERAPEUTICS in Q2 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $74,000 | +100.0% | 17,500 | +50.9% | 0.00% | +200.0% |
| Q4 2021 | $37,000 | +164.3% | 11,600 | -55.0% | 0.00% | – |
| Q2 2021 | $14,000 | – | 25,800 | +122.4% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 11,600 | -3.3% | 0.00% | – |
| Q3 2020 | $6,000 | -50.0% | 12,000 | -38.8% | 0.00% | -100.0% |
| Q2 2020 | $12,000 | -20.0% | 19,600 | -18.0% | 0.00% | 0.0% |
| Q1 2020 | $15,000 | -83.1% | 23,900 | -48.2% | 0.00% | -75.0% |
| Q4 2019 | $89,000 | +345.0% | 46,100 | +40.1% | 0.00% | +100.0% |
| Q3 2019 | $20,000 | +400.0% | 32,900 | +80.8% | 0.00% | – |
| Q1 2019 | $4,000 | -92.3% | 18,200 | -54.6% | 0.00% | -100.0% |
| Q4 2018 | $52,000 | -99.3% | 40,100 | -71.4% | 0.00% | -99.4% |
| Q3 2018 | $7,451,000 | +59.0% | 140,310 | -71.0% | 0.47% | +102.1% |
| Q2 2018 | $4,686,000 | +1337.4% | 483,375 | +9020.3% | 0.23% | +1356.2% |
| Q1 2018 | $326,000 | – | 5,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |